From: Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy
Tumour type | Cell type | Sample number | Cell marker | Location of B cells | Clinical findings | Reference |
---|---|---|---|---|---|---|
Melanoma | B cells | 136 | CD20 | Peritumoral TLS | Better response to ICIs | [75] |
Melanoma | B cells | 164 | CD20 | TLS | Improved OS | [58] |
Sarcoma | B cells | 496 | CD20/CD20 | TLS | Better response to ICIs | [76] |
Breast cancer | B cells | 1200 | CD20 | Intratumoural tissue | Improved DSS | [77] |
Breast cancer (HER2+) | B cells | 136 | CD20 | Intratumoural tissue | Prolonged OS and DFS | [78] |
Breast cancer (TNBC) | B cells | 113 | CD20 | Intratumoural tissue | Prolonged OS and DFS | [78] |
Breast cancer (TNBC) | B cells | 114 | CD20/CD138 | Intratumoural tissue | Improved DFS | [79] |
Colorectal cancer | B cells | 316 | CD20 | stromal | Improved DSS | [80] |
Colorectal cancer | B cells | 557 | CD20/CD138 | Intratumoural tissue | Improved OS | [81] |
Gastric cancer | B cells | 266 | CD20 | TLS | Improved OS | [82] |
Gastric cancer | Bregs | 59 | CD19 | / | Poorer OS | [39] |
Hepatocellular carcinoma | B cells | 120 | CD20 | Intratumoural tissue | Prolonged OS | [83] |
Hepatocellular carcinoma | B cells | 112 | CD19/CD20 | Intratumoural tissue | Improved survival rate | [84] |
Pancreatic cancer | B cells | 28 | CD20 | TLS | Improved OS | [56] |
NSCLC | B cells | 196 | CD20 | TLS | Improved DSS | [44] |
NSCLC | PCs | 207 | CD20/CD138 | Intratumoural tissue | Prolonged OS | [85] |
Renal cell cancer | PCs | 130 | IgG+/IgA+ | TLS | Prolonged PFS | [46] |
Prostate cancer | B cells | 110 | CD20 | Intratumoural tissue | Poorer RFS | [59] |